Shield Therapeutics Share Discussion Threads

[devonlad] 28/9/2023 16:47

Bloke at the top looks like he could do with having some of his own product!

[devonlad] 28/9/2023 16:45

I am in best!

[best1467] 28/9/2023 16:41

Anyone having difficulty joking webinair

[bones698] 28/9/2023 16:09

Seen this before and have to say I'm not sold here . Increasing costs due to expansion to get sales but the cost of that compared to the actual amount of increased sales seems like a false economy . No point spending 20m a year increasing sales to get 15m back in sales . Plus increasing sales is never guaranteed . Either way there is no rush to buy here as things will move slowly and the fact it's trading under the raise price says the market doesn't have a lot of faith in the company to deliver . I'll happily sit on the sidelines and watch for now. Gl

[parob] 28/9/2023 16:00

It's gonna need some patience. The dilution could be much worse, will probably be a few months until we are back at the 12p level but imo buyers around here will do well over mid-long term.

[devonlad] 28/9/2023 15:48

investormeet, got it!

[parob] 28/9/2023 15:43

At least we have more realistic annual prescription targets now.

[parob] 28/9/2023 15:40

I still feel positive about the long term despite todays news but my targets aren't as high now.

[napoleon 14th] 28/9/2023 15:39

PATT - best is right - bunch of crooks. Just understand yesterday's price move.....

[parob] 28/9/2023 15:39

The only thing that makes me feel better about it is to buy more under the placing price which I've been doing today whilst the negativity is at the extremes.

[purchaseatthetop] 28/9/2023 15:26

FFs sake. They always were going to need to raise cash. Was it better to wait and then have everybody wondering when? They got it done and anybody can buy at less than the placing price. Bargain bucket.

[devonlad] 28/9/2023 15:23

got a link to the meeting?

[qipincha] 28/9/2023 15:21

meeting at 4:30 to find out

[encarter] 28/9/2023 15:17

They said this in April "completion of the Viatris agreement and our GBP30 million financing set Shield up for a strong future, with the resources to support our planned operations to cash flow break even, expected in Q4 2024."The they got the AOP cash on top of that and now this. Wtf?

[qipincha] 28/9/2023 15:04

hopefully, this is the last fund raising and we will head north again

[lako42] 28/9/2023 15:01

I notice that there is no mention of the directors taking up extra shares through these placings.

What a disgrace if so.

[best1467] 28/9/2023 14:38

Yes These clowns managed to grow sales on average last months 26% after 100 million or more raised in the last couple of years with100 strong team in the biggest market on the planet and Nordgine managed 19 % in 3/4 of uk and Germany with around 18 sales team part time.
I would put good money not a single mention of the shenanigans over the last days in the Staged presentation

[parob] 28/9/2023 14:37

Reckon we see decent bounce from here

[reviewwworld] 28/9/2023 14:34

And now it's 7.40pAnd rightly so. The bears got this right 2 years ago and were demonised

[napoleon 14th] 28/9/2023 14:32

I have two fundraisers in my PF this month.

EEE at 4p to drill faster and further on the huge potential at Pitfield.
Once that was announced, share price retreated from 5p to 4.25p AFTER the raise was announced.

STX fell 33% BEFORE the day of the fundraise announcement, which says it all.

I'll do the FDA form as a matter of principal but won't hold my breath...

[parob] 28/9/2023 14:31

This drop is crazy. More added!

[zeus19] 28/9/2023 14:16

Cavendish just released this. 50p Target PriceSHIELD THERAPEUTICS* $26.1m fundraise ($20.0m debt)/$6.1m equity) Shield raised $26.1m through a $20m term loan facility with SWK Holdings (unconditional) and $6.1m equity placing to fund several initiatives to drive improvement in gross-to-net (GTN) prices (including new field access team), fund the working capital needs (inventories and receivables) of the US growth story and repay the $5.7m AOP Health convertible loan. The interims and Q3 update clearly show the fruits of the Viatris collaboration, with covered lives increasing 20% to 123m (vs. 100m) and strong prescription momentum (+52% Q2 vs Q1 rising to +80% Q3 vs Q2) driving volume growth. However, the GTN price ($119) was lower than expected, but we appreciate that the changes (modifying patient access programmes, field access team, etc.) being made should address this point. Our forecasts are revised significantly for 2023E, although the long-term outlook remains very positive and, therefore, has less of an impact on the target value. We reduce our target price by 15% to 50p, reflecting the equity dilution and lower profitability. - $26.1m debt/equity fundraise will be used to fund both a new sales access team to optimise gross-to-net price and working capital needs, and for repayment of $5.7m AOP Health convertible loan. The equity component comprised a placing and subscription of 62.4m ordinary shares at 8p ($6.1m). Additionally, there is a Retail Offer which could raise a maximum $1.4m. SWK Holdings is providing a 5-year term loan (2-year interest only at SOFR+9.25% - ie. 14.6%). - Interim results. Revenues +66% to $4.3m; adjusted loss before tax of $11.6m (vs. -$12.4m) and a loss per share of 2.0c (vs. -7.0c). Period-end cash and net cash were $13.6m and $7.9m, respectively. Whilst c.50% of scrips are reimbursed by commercial payers, the balance is subsidised through patient assistant programmes, resulting in a net average sales price of c.$119 per prescription (vs. $124 and $144 in H1 and FY 2022) – target is c.$220-240 in 2025. - Substantial growth momentum highlights the early impact of the expanded commercial team, with average monthly scrip growth (May to August) up 26%; first-time writers +157% in Q2 vs. Q1; NRx up 63% vs. Q1; and, importantly, repeat writers +73% vs. Q1. Accrufer was also added to the two largest US Medicaid programmes in California and New York. - Field access team to address GTN. We can clearly see how the measures being taken (modifying patient access programme and adding a 12-person team in 2024) can have a positive effect on GTN in 2024 with line of sight to achieving $220-240 per scrip in 2025, through increasing the number of prior authorisations into payers by HCPs (and leaving sales force to sell), which in turn should drive revenue-generating prescriptions and lift the GTN price. - Forecasts. We re-cast our forecasts using Q3/9M US prescription volumes as a base (FY 23 -12% lower TRx at c.115,000) and a substantially (-30%) lower GTN price forecast for 2023 ($123 vs $175). Adjusted pre-tax loss is $9m (47%) higher at c.$28.9m for FY 23. - Valuation. We reduce our target price by 15% to 50p based on a rNPV, which reflects the c.7% dilution as well as pushing our profitability forecast out by approximately one year.